On Monday, November 25, 2012, GlycoBioSciences (plaintiff) recorded a suit against Innocutis and DARA
BioSciences
(defendants) for patent infringement in the U.S. District Court of Columbia
(case no. 1:12-cv-01901).
GlycoBioSciences is a pharmaceutical company exclusively
devoted to the sale, licensing and development of IPM (ionic polymer matrix)
technology and products. In 2008, GlycoBioSciences purchased the assets of LAM pharmaceutical
and launched Hylase, a tropical wound gel acting as a lubricant and shock
absorber for joints, used to treat knee pain. Innocutis is a pharmaceutical and
medical device company specializing in the development and commercialization of
therapies and devices focused on medical treatment of dermatological
conditions. DARA BioSciences is a specialty pharmaceutical company
focused on the development and commercialization of oncology treatment and
supportive care products.
The patents
involved in this suit are:
|
Patent
Number
Current
Assignee[i]
|
Issued Date
|
Expiration Date[ii]
|
Title
|
|
|
Apr 20,
2004
|
Sep 29,
2015
|
Topical drug preparations
|
|
|
Sep 19,
2000
|
Sep 29,
2015
|
Topical drug preparations
|
Note: Table Information sourced from Maxval’s
Assignment Database.
According to the complaint, GlycoBioSciences developed IPM
Diclofenac pain gel and obtained FDA approval for Hylase. Plaintiff alleges
that Innocutis markets FDA approved drug Bionect®,
which includes the formulation claimed in the above patents. Bionect® acts as a lubricant on the
skin by restoring moisture and preventing friction or abrasion. It is also
advertised as a tropical treatment of dermatological conditions. DARA is the
exclusive licensee of Innocutis for certain indications of Bionect®.
The
plaintiff in the past had filed suit against the companies below:
|
Company
Name
|
Case Number
|
Date Filed
|
Status
|
|
Jun 23, 2011
|
Pending
|
||
|
Nycomed US,
Pharmaderm
and Jagotec
|
Mar 17, 2011
|
Pending
|
If you are interested
in knowing more about the above case, please contact
us.
For more details,
visit MaxVal-IP and subscribe to our Litigation Alerts.
[i] MaxVal offers Patent Assignment Alert service where subscribers
receive email alerts when assignments relating to target applications, patents
or entities of interest are recorded.
[ii] Expected expiration date. Patent Term
Estimator is a free web-based tool that automatically calculates patent terms and
expiration dates for U.S. utility patents.
No comments:
Post a Comment